Live Oak Private Wealth LLC Buys 5,593 Shares of Icon Plc $ICLR

Live Oak Private Wealth LLC lifted its position in Icon Plc (NASDAQ:ICLR) by 44.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,233 shares of the medical research company’s stock after buying an additional 5,593 shares during the quarter. Live Oak Private Wealth LLC’s holdings in Icon were worth $3,191,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ICLR. Artisan Partners Limited Partnership increased its holdings in shares of Icon by 67.4% in the second quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after purchasing an additional 2,893,946 shares during the period. Financiere des Professionnels Fonds d investissement inc. boosted its stake in Icon by 31.0% during the second quarter. Financiere des Professionnels Fonds d investissement inc. now owns 50,212 shares of the medical research company’s stock valued at $7,303,000 after buying an additional 11,894 shares during the period. American Century Companies Inc. grew its position in Icon by 11.2% during the second quarter. American Century Companies Inc. now owns 531,395 shares of the medical research company’s stock worth $77,292,000 after buying an additional 53,458 shares in the last quarter. Equity Investment Corp bought a new position in Icon in the 2nd quarter worth about $82,264,000. Finally, DAVENPORT & Co LLC purchased a new stake in shares of Icon in the 2nd quarter valued at about $403,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Price Performance

Shares of Icon stock opened at $182.84 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. Icon Plc has a 52-week low of $125.10 and a 52-week high of $228.29. The company has a fifty day moving average of $175.36 and a 200-day moving average of $170.06. The stock has a market capitalization of $14.77 billion, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 3.39 and a beta of 1.25.

Analyst Ratings Changes

ICLR has been the subject of several recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Icon in a report on Monday, December 22nd. BMO Capital Markets assumed coverage on shares of Icon in a research report on Thursday, November 13th. They set a “market perform” rating and a $175.00 target price for the company. Barclays boosted their price target on shares of Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Rothschild & Co Redburn upgraded shares of Icon from a “neutral” rating to a “buy” rating and raised their price objective for the company from $184.00 to $236.00 in a research report on Wednesday, September 3rd. Finally, Jefferies Financial Group lowered shares of Icon from a “buy” rating to a “hold” rating and cut their target price for the stock from $220.00 to $175.00 in a research report on Tuesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat.com, Icon presently has a consensus rating of “Moderate Buy” and an average target price of $205.31.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.